Assessment of proliferating cell nuclear antigen immunostaining in parotid tumors.
We evaluated the prognostic value of immunostaining proliferating cell nuclear antigen (PCNA) by using a monoclonal antibody (PC10) in patients with parotid tumors. Twenty-seven cases were studied. Immunohistochemical studies were carried out on paraffin-embedded tissues from the patients, and the PCNA index was calculated as the percentage of positively staining tumor cells. The PCNA index ranged from 0.1 to 65.3%. We divided the 27 lesions into three groups histologically: group A with benign pleomorphic tumors (11 cases), group B with low-grade malignant tumors (5 cases), and group C with high-grade malignant tumors (11 cases). The mean PCNA index was 0.7% in group A, 2.0% in group B, and 23.1% in group C. The clinical data revealed a significantly higher local tumor recurrence and mortality rate in group C than in groups A and B. We conclude that PCNA may be used as an important indicator for determining clinical prognosis in parotid tumors.
Takahashi
M
M
Department of Otolaryngology, Asahikawa Medical School, Hokkaido, Japan.
Adachi
T
T
Matsui
R
R
Miyokawa
N
N
D008949:Adenoma, Pleomorphic / Q000473:pathology; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D002277:Carcinoma / Q000473:pathology; D018267:Carcinoma, Acinar Cell / Q000473:pathology; D003528:Carcinoma, Adenoid Cystic / Q000473:pathology; D018277:Carcinoma, Mucoepidermoid / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000473:pathology; D004396:Coloring Agents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D010307:Parotid Neoplasms / Q000473:pathology*; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis*; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D004396:Coloring Agents; D018809:Proliferating Cell Nuclear Antigen